The University of Southampton
University of Southampton Institutional Repository

Current drug therapy for prostate cancer: an overview

Current drug therapy for prostate cancer: an overview
Current drug therapy for prostate cancer: an overview
Prostate cancer is the most common cancer amongst men in the USA and the second most common malignant cause of male death worldwide after lung cancer. The life time risk of having microscopic evidence of prostate cancer for a 50 year old man in 42%. Prostate cancer is thus becoming an increasingly significant global health problem in terms of mortality, morbidity, as well as economically. This review, discusses current medical therapeutic options for prostate cancer including traditional treatments using luteinising hormone releasing analogues (LHRH), anti-androgens and estrogen treatments, and the use of novel drugs directed against molecular targets considered important in oncogenesis and metastasis. Prostate cancer chemoprevention using 5_-reductase inhibitors and the role of gene therapy are also considered.
prostate cancer, current drug therapy, review
1568-0118
603-612
Stewart, A.B.
b0ebb7e8-6846-4155-9203-28d13bdbf7be
Lwaleed, B.A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Douglas, D.A.
56600b1c-3151-41f7-b370-4b008df2e777
Birch, B.R.
8579836b-80ab-4802-930c-728daeb4a95e
Stewart, A.B.
b0ebb7e8-6846-4155-9203-28d13bdbf7be
Lwaleed, B.A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Douglas, D.A.
56600b1c-3151-41f7-b370-4b008df2e777
Birch, B.R.
8579836b-80ab-4802-930c-728daeb4a95e

Stewart, A.B., Lwaleed, B.A., Douglas, D.A. and Birch, B.R. (2005) Current drug therapy for prostate cancer: an overview. Current Medicinal Chemistry - Anti-Cancer Agents, 5 (6), 603-612. (doi:10.2174/156801105774574658).

Record type: Article

Abstract

Prostate cancer is the most common cancer amongst men in the USA and the second most common malignant cause of male death worldwide after lung cancer. The life time risk of having microscopic evidence of prostate cancer for a 50 year old man in 42%. Prostate cancer is thus becoming an increasingly significant global health problem in terms of mortality, morbidity, as well as economically. This review, discusses current medical therapeutic options for prostate cancer including traditional treatments using luteinising hormone releasing analogues (LHRH), anti-androgens and estrogen treatments, and the use of novel drugs directed against molecular targets considered important in oncogenesis and metastasis. Prostate cancer chemoprevention using 5_-reductase inhibitors and the role of gene therapy are also considered.

This record has no associated files available for download.

More information

Published date: 2005
Keywords: prostate cancer, current drug therapy, review

Identifiers

Local EPrints ID: 19302
URI: http://eprints.soton.ac.uk/id/eprint/19302
ISSN: 1568-0118
PURE UUID: c2c4af2b-e9bd-4c25-9cce-b87cf322faca

Catalogue record

Date deposited: 01 Feb 2006
Last modified: 15 Mar 2024 06:13

Export record

Altmetrics

Contributors

Author: A.B. Stewart
Author: B.A. Lwaleed
Author: D.A. Douglas
Author: B.R. Birch

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×